The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated multicenter retrospective analysis of systemic treatments in well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
 
Angelo Pirozzi
No Relationships to Disclose
 
Celine Hoyek
No Relationships to Disclose
 
Fares Jamal
No Relationships to Disclose
 
Caden Collins
No Relationships to Disclose
 
Edwar Kounsselie
No Relationships to Disclose
 
Abdullah Alsulaiman
No Relationships to Disclose
 
Amal Youssef
No Relationships to Disclose
 
Daniel Ahn
Stock and Other Ownership Interests - Lilly; Natera
Consulting or Advisory Role - Advanced Accelerator Applications; Daiichi Sankyo/Astra Zeneca; Eisai; Exelixis; Genentech/Roche; Incyte; Incyte; Novartis
Research Funding - AstraZeneca; Bayer
 
Tanios Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Timothy Hobday
Research Funding - Novartis (Inst)
 
Jason Starr
Consulting or Advisory Role - Exelixis
Research Funding - Amgen (Inst); Aminex (Inst); Arcus Biosciences (Inst); Camurus (Inst); RayzeBio (Inst); Viewpoint Molecular Targeting (Inst)
 
Thorvardur Halfdanarson
Consulting or Advisory Role - Advanced Accelerator Applications (Inst); Biomea Fusion; Boehringer Ingelheim; Camurus (Inst); Crinetics Pharmaceuticals (Inst); Curium Pharma; Exelixis; Ipsen (Inst); ITM Isotope Technologies Munich (Inst); Perspective Therapeutics (Inst); Tersera; Viewpoint Molecular Targeting (Inst)
Research Funding - Advanced Accelerator Applications (Inst); Camurus (Inst); Crinetics Pharmaceuticals (Inst); ITM Isotope Technologies Munich (Inst); Novartis (Inst); Perspective Therapeutics (Inst); Thermo Fisher Scientific (Inst); Turnstone Bio (Inst)
(OPTIONAL) Uncompensated Relationships - North American Neuroendocrine Tumor Society
 
Patrick McGarrah
No Relationships to Disclose
 
Mohamad Sonbol
Honoraria - Novartis
Consulting or Advisory Role - Bayer (Inst); Boehringer Ingelheim (Inst)
Research Funding - Lilly (Inst); Taiho Oncology (Inst)